Try our Advanced Search for more refined results
Life Sciences - April, 2012
290 articles
- Becton Asks High Court To Refuse Retractable's IP Appeal
- Senate Panel Fattens USDA Food Inspection Budget
- High Court Won't Weigh Suit Over Generic Reglan Labeling
- Ex-Pfizer Saleswoman Says She Was Fired Over Pregnancy
- Warner Chilcott Weighs Sale To Boost Shareholder Value
- Losing The 'Empty Chair' At Trial
- Judge OKs Mylan's Acne Generic But Keeps Patent Intact
- Ex-Squire Sanders IP Attorney Jumps To Carr & Ferrell
- Q&A With Paul Hastings' Gerald Flattmann
- Jones Day, Brown Rudnick Aid Hologic In $3.7B Gen-Probe Buy
- Conceptus Shuns $19M IP Deal As Rival Pulls Contraceptive
- Darvocet Plaintiffs Can't Take Generics Dismissal To 6th Circ.
- Merck Defeats Mylan's Challenge To Zetia, Vytorin Patent
- Merck Wins Patent Rights Suit Over Singulair Imports
- Otsuka Slaps Amneal With IP Suit Over Generic Abilify
- Vivus' Erectile Dysfunction Drug Stendra Wins FDA Approval
- China Cord Blood Closes $65M Debt Financing With KKR
- Treasury Fines Medical Equipment Maker Over Iran Shipment
- HHS Has Final Say On Medicare Device Coverage: 4th Circ.
- FDA Chews Out Angiomax Maker Over Promo Materials
- Warner Chilcott Targets Ranbaxy's Osteoporosis Generic
- New FDA Rule Broadens Scope Of Clinical Investigator Bans
- Q&A With Gibson Dunn's Mark Perry
- Subleasing — More Than Meets The Eye
- Judge Hints At Collusion In $12M Boiron False Ad Settlement
- FDA Advisory Panel Backs Cameron's New Defibrillators
- High Court Asked To Review Antitrust Standing Rule
- FDA Exploring '1-Page Solution' to Med Guide Size
- Saint-Gobain Not Owed Higher Infringement Bar, SG Says
- Medical Co. Launches $90M Suit Over Mad Cow Contamination
- Health Law Challengers Make One More Plea On Tax Issue
- SEC Sets Sights On Bristol-Myers In Foreign Bribery Crackdown
- Dialysis Co. Says Prior Deal Bars Some FCA Claims
- King & Spalding Nabs 2 Cadwalader Pharma Litigation Pros
- Abbott Again Moves To Block Generic Version Of Zemplar
- Q&A With WilmerHale's Lia Der Marderosian
- 13 States Want In On $90M Medicaid Suit Against Healthpoint
- FDA Doesn't Have The Discretion It Thought It Had
- Operationalizing Law Department Performance Metrics
- Judge Asks GSK To Tweak Details In $10.4M Paxil Settlement
- FTC Loses Androgel Pay-For-Delay Appeal In 11th Circ.
- Watson To Pay $5.6B For Generic-Drug Maker Actavis
- Pfizer Off-Label Marketing Suit Pushed Toward Dismissal
- Icahn Ditches Amylin Suit After Chat With CEO
- Purdue Seeks To Stop Watson's Reformulated Oxy Generic
- Pitt's Award Doubled To $74M For Varian's Willful Infringment
- FDA User Fee Bill Clears 1st Legislative Hurdle
- Amgen To Shell Out $669M For Turkish Drugmaker
- Cellectis Faces Rival's 10th Genome Engineering IP Suit
- Q&A With Morgan Lewis' Randall Sunberg
- Boston Scientific Reports Death From Defibrillator Glitch
- The Mayo Test: Impact On Personalized Medicine And Beyond
- Ardea Sued Over $1.3B AstraZeneca Deal
- Research Co. Makes Peace With FDA Over Suspect Drug Tests
- FDA's Nanotech Safety Rules May Not Help Cos. Avoid Risk
- Darvocet Judge Won't Seek States' Input On Lilly Liability
- CMS Rejects HHS Call For Off-Label Avastin Endorsement
- FDA User Fee Bill Faces 1st Test In Senate Panel Vote
- ViroPharma Loses Bid To Block Generic Vancocin
- Roche Recalls Potentially Faulty Heart Attack Test Tools
- Sun Pharma, Mylan Enter Growing Pool Of Zyprexa Generics
- Innisfree Snags Takeover Pro From Sullivan & Cromwell
- Merck Ducks Missouri Vioxx Claims Linked To Settlements
- Pain Drug Co. Treated To Shareholder Suit Over Exec's Exit
- Actos May Increase Bladder Cancer Risk, Health Canada Warns
- Q&A With Fish & Richardson's Jonathan Singer
- Mylan Loses Bid To Block Teva's Provigil Market Rights
- A Bitter Pill: Personal Liability For Health Care Execs
- InfuPharma Targets Insurer For Avastin Defense
- Ill. Dad Slaps Cochlear Implant Maker With Class Action
- Trustees Report Leads To Calls For Medicare Reform
- Fired CR Bard Exec Sues Over Age Bias
- FDA Unveils Rules For Nanotech In Food, Cosmetics
- Standstills And No Shops: A Potentially Dangerous Mix
- Med Industry Presses FDA To Modernize Clinical Trial Rules
- BVF Partners Pursues Appeal Over Genetics Co. Sale
- Doctors Slam Federal Stem Cell Research Funding In DC Circ.
- FDA Bolsters Post-Market Scrutiny Of Drugs
- OrbiMed Debuts $222M Israeli Life Sciences Venture Fund
- Q&A With King & Spalding's Seth Lundy
- FDA Spotlights 'Prominent Risks' Of Cameron Defibrillator
- Judge Expedites Icahn's Suit Over $3.5B Amylin Takeover Bid
- Merck Escapes High Court Hearing In $26M Vioxx Suit
- Davis Wright Adds Ex-MoFo Patent Pro In San Fran
- Apotex Sues Pfizer, UCB, Others Over Blood Pressure Meds
- Mayer Brown Reps Nestle On $12B Purchase Of Pfizer Unit
- Between You And Me: FDA Comments Not Disclosure Events
- PPACA: Illuminating The Dark Side Of Health Care
- Covington Aids AstraZeneca In $1.3B Ardea Biotech Buy
- Graceway's Ch. 11 Plan Gets Nod As Judge Quells IRS Worries
- Enzo Targets Siemens Over Viral Load Testing Patent
- Anti-Mensing Bill Could Topple FDA's Generics Framework
- Case Study: Caraco V. Novo Nordisk
- How They Won It: Fish & Richardson Triumphs For Mayo
- Wyeth Hit With $4M Jury Verdict In Prempro Suit
- EU Committee Backs Bristol, Astra Diabetes Drug Forxiga
- FDA Warns Of More Eye Infections Related To Recalled Dye
- Novartis Agrees To Stricter Safety Measures For MS Drug
- Warning! FDA Is Flexing Its PMR Enforcement Muscle
- Aspen Pays $263M For GSK's Zantac, Other OTC Drugs
- Judge Balks At ViroPharma's Bid To Halt Vancocin Generics
- FDA Head Defends Tech Upgrade Progress To Senate Panel
- Fed. Circ. Nixes Inventor's Anti-Coagulant Patent App
- Generics Industry's Drug Shortage Plan Wins FDA Support
- McDermott Snags Former McGuireWoods Life Sciences Chair
- Judge OKs $321.6M Fine Against Merck For Vioxx Marketing
- Fentanyl Patches Can Be Deadly To Children, FDA Warns
- PETA Agrees To Put Down Merck Securities Suit
- Elan, Pfizer Didn't Hype Alzheimer's Drug, 2nd Circ. Hears
- Ivera Targets Catheter Connections Over Medical Device IP
- J&J Faces Canadian Suit Over Surgical Mesh Complications
- CIT Upholds Applikon's Win In Bioreactor Duty Fight
- FDA: Shining A New Light On Benefit-Risk Analysis
- Biotech Co. Human Genome Rejects $2.6B Bid From GSK
- J&J's $21B Synthes Buy Gets EU Nod After Divestiture
- New Bill Would Let Generics Makers Update Own Labels
- FDA Rejects Approval Of Change To Nuvo Anesthetic Cream
- Lupin Pushes Fed. Circ. To Reconsider Fortamet Injunction
- House Mulls Controversial FDA Mission Change
- Jury Sides With Pitt In $37M Radiation Patent Row With Varian
- Industry Drug-Tracking Idea Not Worth The Cost, FDA Says
- Mylan Fights FDA On Teva's Provigil Market Rights
- Merck Chalks Up 2nd Fosamax Trial Win In NJ
- Endo Pharma Freed From 14 Suits In Darvocet, Darvon MDL
- Pfizer Sells Land Near Old Brooklyn Factory To Local Investors
- Medical Lab Rep Still Shunting Sales To Rival, Suit Says
- Senate Bill Expands Pediatric Drug Regulation, Incentives
- Roche Gives Up On $6.2B Hostile Bid For Illumina
- Limiting The Impact Of Prometheus
- Docket Diving: Strategic Uses Of Online Docket Info
- Lilly Sues Apotex Over Lung Cancer Drug Patent
- Generics' High Court Win Opens New Battleground With Pharmas
- GSK Pays $2.6M To Exit Idaho Drug Price-Fixing Suit
- Fed. Circ. Again Eyes Ban On Lupin's Generic Fortamet
- Pfizer Nears $9B Sale Of Baby Formula Unit To Nestle
- Report Knocks FDA For Lagging On Critical IT Upgrades
- Hospira Drug Shortage Harmed Vitamin-Deficient Patients: Suit
- Drugmakers Spar Over Clinical Trial Rules For Biosimilars
- J&J Sued Over Death Of Baby Who Took Recalled Tylenol
- JPML Consolidates Zoloft Birth Defect Suits In Pa.
- Paraplegic's Medtronic Suit Preempted, Split 9th Circ. Rules
- Pay-For-Delay Suits Against Pfizer Consolidated In Tenn.
- Merck To Face Propecia Sexual Dysfunction MDL
- Cozen O'Connor Fattens IP Practice With Duane Morris Team
- FDA Warns Dental Device Maker Over Unapproved Use Ads
- High Court OKs Patent Use Challenges By Generic Drug Cos.
- FTC: Weeding Through Substantiation Of Health Care Ads
- Case Study: Marine Polymer V. HemCon
- Judge Finds No New Misconduct By Pfizer In Celebrex Suit
- High Court Considers Drug Sales Reps' OT Status
- Merck Betting Up To $1B On Endocyte's Cancer Treatment
- Dey Didn't Infringe Asthma Drug Patent, Fed. Circ. Rules
- Allergan Eyes Generics Makers In Glaucoma Patent Row
- Fed. Circ. Says Hard Facts Key To Obviousness Rulings
- Keller and Heckman Makes Inroads In EU With New Paris Office
- Fed. Circ. Won't Protect Bayer From Generic Yasmin
- Sanofi Accuses FedEx Of Wrecking $7M Vaccine Shipment
- Learning From Omeros' FCA Suit
- UCB Targets Covidien Unit Over Ritalin Patent
- Genzyme Negligence Suit Won't Get High Court Hearing
- High Court Refuses Pfizer Appeal Over Novartis Hemophilia IP
- Medicis, Perrigo Reach Licensing Deal on Loprox Shampoo
- Drug Reps' OT Case To Take Center Stage At High Court
- U. Of Kansas Wins Inventor Credit For NIH Cancer Drug
- ViroPharma Sues FDA To Block Generic Vancocin Release
- Cetero Gets Nod To Auction Assets In Ch. 11
- Texas Agency Gives Go-Ahead To Experimental Stem Cell Use
- FDA Warns Ferring, Says Firmagon Sales Pitch Is Misleading
- Deleted Billing Code Hobbled Orthotics Sales, Co. Contends
- Astellas Unit, Pfizer Sue To Bar Roxane's Generic Tarceva
- Purdue Tries To Knock Out Generic OxyContin ANDA
- Antitrust Challenges To FDA Citizen Petitions: Part 2
- Olympus Faces $2M Fine For Accounting Scandal
- FDA Overstepped In Pet Drug Case, Groups Tell 11th Circ.
- Merck Drugs Tied To Lingering Sex Disorders, FDA Warns
- FDA Experts Push For Wider Anti-Overdose Drug Availability
- Investor Sues To Halt Genstar's $400M Buy Of Research Co.
- Becton Dickinson Loses Bid To Trademark Blood Tube Cap
- Icahn Sues Amylin For Docs On Rebuffed $3.5B Bristol Bid
- US Calls For J&J Exec's Testimony In FCA Kickbacks Case
- FDA Disputes AstraZeneca's Seroquel Exclusivity Claims
- Trading Secrets: An Unwise Move In The Electronic Age
- EU Approves Abbott's Humira For Ulcerative Colitis Use
- Board Pushes For Medical Device Cybersecurity Oversight
- Depomed Targets Impax, Par Over Generic Epilepsy Drug
- FDA Warns ThyssenKrupp Over Wheelchair Lift Defects
- FDA Asks Drug Cos. To Curtail Antibiotics In Livestock Feed
- High Court Again Asked To Mull Patent Evidence Limits
- Fed. Circ. Allows Attys' Fees For Time-Barred Vaccine Claims
- Scottsdale Recoils At Coverage For Defective Wrinkle Meds
- Bayer Can't Sidestep Men's Vitamin False Ad Suit
- Takeda Sales Manager Urges 4th Circ. To Save FCA Case
- Wellbutrin Antitrust Class Survives Bid To Nix Cert.
- J&J Fined $1.2B In Ark.'s Risperdal Marketing Suit
- Gilead Ducks Reinstatement, Back Pay Claims In FCA Suit
- Is Mayo V. Prometheus Really A Game Changer?
- Sidley Helps Takeda With $800M Gout Drugmaker Buy
- Medical Product Maker HemCon Files For Ch. 11
- J&J Unit Loses In Ark.'s Risperdal Marketing Suit
- 2nd Circ. Clears Way For Asbestos Suits Against Pfizer
- Abbott Hit With Shareholder Suit Over Depakote Marketing
- FDA Considers Making Anti-Overdose Drug More Accessible
- 1st Circ. Lets Feds Join Arguments In Pfizer FCA Suit
- FDA Adds Blood Clot Risk Data To Birth Control Labels
- FDA Rejects ViroPharma Testing Plea, OKs Generic Vancocin
- FDA Backs Medtronic Heart Device For Many More Patients
- Journal Won't Pull Article Linking St. Jude Wires To Deaths
- Health Law Will Add $340B To Deficit, Medicare Trustee Says
- Sullivan Aids Amgen On $315M Kidney Drugmaker Buy
- Latham Guides Genstar In $400M Pharma Research Co. Buy
- Shearman Reps Corning In $730M Labware Unit Buy
- New VA Restrictions On Drug Co. Detailing Activities
- Teva Says Wyeth Patent Deal Doesn't Step On Antitrust Law
- Icahn Sues Amylin Over Alleged $3.5B Takeover Bid
- Former Orthofix VP Cops To Paying Kickbacks
- Patton Boggs Takes On 4-Atty IP Team From SNR Denton
- Fosamax Expert Grilled Over Financial Ties To Merck
- ABA Prez Slams Obama's Remarks On High Court Health Ruling
- Ex-Ferring Workers Made $43M On Stolen Drug Info, Suit Says
- FDA Picks 3 Kidney Devices For Fast-Track Approval Program
- Inequitable Conduct Ruling Survives Sanofi Fed. Circ. Appeal
- Jury Awards $225K For Jaw Decay From Novartis Bone Drug
- Eye Laser Maker Clears Up $10.6M Case Over Botched Research
- Whistleblower Pushes For New Look At Abbott Stent Case
- Takeaways From HHS Pharma Compliance Roundtable
- Continuing The Trend: Biomet's FCPA Settlement
- Investors Accuse Chelsea Of Overselling Drug's Potential
- Pharma Groups Urge CMS Not To Limit Drug Price Calculation
- FDA Finalizes Regs On Device Info Requests
- Citing Prometheus, Judge Invalidates 'Abstract' ABL Patents
- 5th Circ. Health Law Challengers Indignant Over AG Letter
- JOBS Act — A Game Changer For Emerging Growth Cos.
- Illumina Backed By Advisory Firm In Roche Proxy Fight
- 2 Cases Remanded To State Court From GSK Avandia MDL
- Antitrust Challenges To FDA Citizen Petitions: Part 1
- Lilly Escapes Dozens Of Darvocet, Darvon MDL Suits
- FDA Panel Backs Astellas Bladder Drug Despite Concerns
- Sunshine Act Authors Pressure CMS For Final Rule By June
- AstraZeneca Claims FDA Skirted Seroquel Exclusivity
- US Trustee Slams Releases In Graceway Ch. 11 Plan
- Mylan Generic Treads On AstraZeneca Patents, Fed. Circ. Hears
- Mylan Aims To Nix FDA Approval Of Teva's Generic Provigil
- Holder Defends Obama's Comments On High Court To Judge
- AR Holdings Claims Par Pharma Infringed Gout Drug Patent
- Spectrum To Pay $206M For Cancer Drug Manufacturer
- Case Study: Kendall V. Hoffman-LaRoche
- Predictive Coding — Cost Savings If Investment Is Made
- Covidien's $300M Oridion Buy Latest In Shopping Spree
- Senate Drafts Plan To Speed Up FDA Drug Approval
- SEC Sticks To Tough Stance On SOX Clawback Provision
- FDA Must Do More To Ensure Drug Import Safety, Report Says
- Endo Cut Loose From 9 Suits In Darvocet, Darvon MDL
- Holder Backs Obama's ACA Remarks Amid 5th Circ. Flap
- St. Jude Yanks Heart Wires Over Erosion Concerns
- Teva, Cephalon Sue FDA Over Generic Provigil Exclusivity
- Reps. Tout Bill Giving Generics Cos. Leg Up On Exclusivity
- Prescription Drug Spending Ticked Up To $320B In 2011
- J&J's Levaquin Trial Win Upheld Over Jury Selection Beef
- Easing The Dissent's Concerns In Marine Polymer
- Challenging The Legality Of Copay Coupons
- UK Tells Docs To Ditch Stryker-J&J Hip Replacements
- More Fake Foreign Avastin Found, FDA Warns
- Procter & Gamble Drops Out Of Somaxon's OTC Silenor Effort
- Pharma Group Pans FDA Guidance On Off-Label Info Sharing
- American Regent Issues Another Recall Over Faulty Vials
- Tech, Life Sciences Cos. Vulnerable To Activist Takeovers
- IRS Objects To Graceway's Ch. 11 Plan Over Setoff Rights
- FDA Says Astellas' Bladder Drug Poses Heart, Liver Risks
- Akzo Nobel Escapes $421M Medicaid Kickback Suit
- Biomet Offers $280M For Johnson & Johnson Trauma Biz
- Judge Rules Allergan's Sanctura XR Patents Invalid
- K&L Gates Brings Duane Morris Pharma Pro To Pittsburgh
- Speedy FDA Drug Reviews On The Horizon
- Feds Seek To Weigh In On Pfizer Exec's 1st Circ. FCA Appeal
- Genzyme Beats Investor Suit Over Stock Plunge
- Teva Launches Generics Of Hypertension Drugs Avapro, Avalide
- Relovair Bet Fuels Glaxo's $213M Theravance Stake Buy
- Obama Says High Court Should Show Restraint On Health Law
- Judge Knocks Out Stryker Securities Fraud Class Action
- Illumina's Board Rejects $6.5B Cash Offer From Roche
- Medtronic Will Pay Investors $85M To End Off-Label Suit
- Latham Attracts IP, Life Sciences Transaction Pro From Wilson
- Class Claims Kept Intact In $100M Bayer Sex Bias Suit
- 3rd Circ. Lets Insurers Pass The Bill For Catheter-Slur Defense
- PETA Sues Merck Over Research Animals' Living Conditions
- Ex-Bristol Myers Exec Settles SEC Profit Inflation Suit
- Bayer Gets 3 False Ad Class Actions In NJ Nixed
- Bayer's $400M Cipro Payout Strangled Market, Consumers Say
- ITC To Probe Invisalign Rival's Allegedly Crooked Imports
- Federal Preemption Developments Since PLIVA V. Mensing